Physician profile
Jonathan Lorenzana
NPI 1194130880
$3,535.53
in general payments reported to CMS, 2019-2025
14 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 87% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $268 · 2022: $972 · 2023: $950 · 2024: $108 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Travel and Lodging: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.08 |
| Travel and Lodging | $445.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,509.49 | 2020-2025 | |
| Mission Medical Distribution, LLC | $574.20 | 2023-2025 | |
| Stryker Corporation | $310.92 | 2022-2023 | N/A |
| Biocomposites INC | $299.87 | 2023-2025 | Stimulan |
| Imbed Biosciences INC. | $279.84 | 2023 | |
| Orthofix Medical, INC. | $233.50 | 2019-2025 | Trinity Elite, Truelok, Truelok System |
| Anika Therapeutics, INC. | $81.55 | 2022-2023 | Tactoset, X-Twist, Toe Motion |
| Osteomed LLC | $73.05 | 2019 | |
| Smith+Nephew, INC. | $48.49 | 2022-2023 | Regranex, Collagenase Santyl |
| Indivior INC. | $30.84 | 2019 | |
| Arthrex, INC. | $30.00 | 2025 | |
| Kerecis Limited | $22.91 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Integra Lifesciences Corporation | $20.68 | 2019 | |
| Ibsa Pharma INC. | $20.19 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lorenzana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.